Company / Return on Equity (ROE)
Monopar Therapeutics Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-10.0%
FY2025
5-year range
-172.1% / -10.0%
FY2021-FY2025
Trend
+93.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Monopar Therapeutics reports negative total equity of -10.0% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-10.0% in FY2025.
Improved from -104.2% to -10.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 93.4% year-over-year.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -10.0% | +93.4% |
| FY2024 | -150.4% | -44.3% |
| FY2023 | -104.2% | -211.5% |
| FY2019 | -33.5% | +80.6% |
| FY2018 | -172.1% | -310.9% |
| FY2017 | -41.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026